|
Chronic Total Occlusion Vessel
|
0.100 |
Biomarker
|
disease |
BEFREE |
The application of the retrograde approach has dramatically improved success rates of CTO PCI.
|
30912215 |
2020 |
|
Chronic Total Occlusion Vessel
|
0.100 |
Biomarker
|
disease |
BEFREE |
Between January 2013 and December 2015, a retrospective study was conducted on 1230 consecutive patients with CTO who received PCI <i>via</i> the anterograde approach at the General Hospital of Northern Theater Command.
|
31119138 |
2019 |
|
Chronic Total Occlusion Vessel
|
0.100 |
Biomarker
|
disease |
BEFREE |
The most common causes for the presence of unrevascularized CAD included the presence of chronic total occlusion in the native/graft vessels (49.7%) and diffuse/complex CAD unsuitable for PCI (24.6%).
|
31267799 |
2019 |
|
Chronic Total Occlusion Vessel
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present 10 common problems encountered during CTO PCI and a consensus hierarchical approach to them.
|
30467958 |
2019 |
|
Chronic Total Occlusion Vessel
|
0.100 |
Biomarker
|
disease |
BEFREE |
Procedures in the ULC-PCI group included the use of rotational atherectomy, two-stent bifurcation PCI, and mechanically supported chronic total occlusion PCI.
|
30865912 |
2019 |
|
Chronic Total Occlusion Vessel
|
0.100 |
Biomarker
|
disease |
BEFREE |
Percutaneous coronary intervention on chronic total occlusion causes 2- to 10-fold higher radiation burden on patients and operators compared to standard PCI.
|
30196546 |
2018 |
|
Chronic Total Occlusion Vessel
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
RA was performed in 392 out of 17,919 PCI procedures (2.2% of the PCI cohort) and classified as RA CTO (n=75) and RA non-CTO (n=317).
|
30175961 |
2018 |
|
Chronic Total Occlusion Vessel
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study sought to describe the association between chronic total occlusion (CTO) revascularization (CTO percutaneous coronary intervention [PCI]) and health status in patients with and without cardiomyopathy.
|
30466826 |
2018 |
|
Chronic Total Occlusion Vessel
|
0.100 |
Biomarker
|
disease |
BEFREE |
Intentionally dilating the subintimal space during unsuccessful CTO PCI to facilitate flow through dissection planes and improve success of repeat PCI attempts is a technique used by some hybrid operators, and may improve health status by restoring distal vessel flow despite unsuccessful CTO PCI.
|
29068126 |
2018 |
|
Chronic Total Occlusion Vessel
|
0.100 |
Biomarker
|
disease |
BEFREE |
Complication rates for CTO PCI are more frequent than those reported for non-CTO PCI and were independently associated with retrograde approach, increasing age, and increasing lesion complexity.
|
29808821 |
2018 |
|
Chronic Total Occlusion Vessel
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients with PCI of a CTO lesion only, 87% were in CCS or NYHA functional class ≥2 before the index procedure vs. 22% at follow-up.
|
28425767 |
2017 |
|
Chronic Total Occlusion Vessel
|
0.100 |
Biomarker
|
disease |
BEFREE |
Between 2004 and 2012, 1,320 consecutive patients underwent PCI for CTO, 27.4% (362/1320) of whom were diabetics.
|
27890859 |
2017 |
|
Chronic Total Occlusion Vessel
|
0.100 |
Biomarker
|
disease |
BEFREE |
Limited data are available regarding the prediction for functional recovery using late gadolinium enhanced magnetic resonance imaging (LGE MRI) after coronary revascularization for chronic total occlusion (CTO PCI).
|
28256296 |
2017 |